Free Trial
→ Trump Orders 'National Digital Asset Stockpile' (From Crypto 101 Media) (Ad) Buy REGN Stock  Free REGN Stock Alerts

Regeneron Pharmaceuticals (REGN) Financials

Regeneron Pharmaceuticals logo
$598.76 +29.85 (+5.25%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Regeneron Pharmaceuticals

Annual Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413
Consolidated Net Income / (Loss)		 636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413
Net Income / (Loss) Continuing Operations		 636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413
Total Pre-Tax Income 		1,225 1,330 2,079 2,554 2,429 3,810 9,326 4,859 4,199 4,780
Total Operating Income		 1,252 1,331 2,080 2,534 2,210 3,577 8,947 4,739 4,047 3,991
Total Gross Profit		 3,711 4,561 5,475 4,728 5,793 7,377 13,634 10,613 11,301 12,232
Total Revenue		 4,104 4,860 5,872 5,146 6,558 8,497 16,072 12,173 13,117 14,202
Operating Revenue		 4,029 4,860 5,872 5,146 6,558 8,497 16,072 12,173 13,117 14,202
Total Cost of Revenue		 393 300 397 418 765 1,120 2,438 1,560 1,816 1,971
Operating Cost of Revenue		 393 300 397 418 765 1,120 2,438 1,560 1,816 1,971
Total Operating Expenses		 2,459 3,230 3,396 2,194 3,583 3,801 4,687 5,874 7,254 8,241
Selling, General & Admin Expense		 839 1,178 1,320 1,127 1,342 1,346 1,825 2,116 2,631 2,954
Research & Development Expense		 1,621 2,052 2,075 1,469 2,450 2,735 2,908 3,848 4,625 5,233
Other Operating Expenses / (Income)		 - - - -402 -209 -280 -46 -90 -2.10 53
Total Other Income / (Expense), net		 -27 -1.80 -1.10 19 219 234 379 120 152 789
Interest Expense		 - 7.20 25 28 30 57 57 59 73 55
Other Income / (Expense), net		 -13 5.40 24 47 250 291 436 179 225 844
Income Tax Expense		 589 434 880 109 313 297 1,251 520 246 367
Basic Earnings per Share		 $6.17 $8.55 $11.27 $22.65 $19.38 $32.65 $76.40 $40.51 $37.05 $40.90
Weighted Average Basic Shares Outstanding		 103.06M 104.70M 106.30M 107.90M 109.20M 107.60M 105.70M 107.10M 106.70M 107.90M
Diluted Earnings per Share		 $5.52 $7.70 $10.34 $21.29 $18.46 $30.52 $71.97 $38.22 $34.77 $38.34
Weighted Average Diluted Shares Outstanding		 115.23M 116.30M 115.90M 114.80M 114.60M 115.10M 112.20M 113.50M 113.70M 115.10M
Weighted Average Basic & Diluted Shares Outstanding		 103.10M 104.70M 106.30M 109.28M 110.02M 107.13M 108.54M 109.33M 109.76M 109.32M

Quarterly Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Income / (Loss) Attributable to Common Shareholders		 1,316 1,197 818 968 1,008 1,160 722 1,432 1,341 918 809
Consolidated Net Income / (Loss)		 1,316 1,197 818 968 1,008 1,160 722 1,432 1,341 918 809
Net Income / (Loss) Continuing Operations		 1,316 1,197 818 968 1,008 1,160 722 1,432 1,341 918 809
Total Pre-Tax Income 		1,510 1,325 858 1,083 1,111 1,148 701 1,628 1,493 958 905
Total Operating Income		 1,224 1,147 947 1,017 1,111 973 751 1,070 1,180 990 592
Total Gross Profit		 2,618 2,874 2,705 2,753 2,926 2,917 2,711 3,067 3,230 3,224 2,564
Total Revenue		 2,936 3,414 3,162 3,158 3,363 3,434 3,145 3,547 3,721 3,789 3,029
Operating Revenue		 2,936 3,414 3,162 3,158 3,363 3,434 3,145 3,547 3,721 3,789 3,029
Total Cost of Revenue		 318 541 458 405 436 517 434 480 491 565 464
Operating Cost of Revenue		 318 541 458 405 436 517 434 480 491 565 464
Total Operating Expenses		 1,395 1,727 1,758 1,737 1,815 1,944 1,960 1,997 2,050 2,234 1,973
Selling, General & Admin Expense		 529 661 601 652 641 738 689 759 714 792 633
Research & Development Expense		 911 1,073 1,157 1,085 1,175 1,207 1,256 1,224 1,328 1,426 1,340
Other Operating Expenses / (Income)		 -46 -6.60 -0.50 -0.60 -0.50 -0.50 15 15 8.00 16 0.00
Total Other Income / (Expense), net		 286 178 -89 66 -0.20 175 -51 559 314 -32 313
Interest Expense		 15 17 18 19 18 18 16 15 14 11 8.70
Other Income / (Expense), net		 301 195 -71 85 18 193 -35 573 327 -22 322
Income Tax Expense		 194 128 40 115 103 -12 -21 196 152 40 96
Basic Earnings per Share		 $12.31 $11.18 $7.64 $9.05 $9.48 $10.88 $6.70 $13.25 $12.40 $8.55 $7.58
Weighted Average Basic Shares Outstanding		 106.90M 107.10M 107.10M 107M 106.30M 106.70M 107.80M 108.10M 108.10M 107.90M 106.70M
Diluted Earnings per Share		 $11.66 $10.48 $7.17 $8.50 $8.89 $10.21 $6.27 $12.41 $11.54 $8.12 $7.27
Weighted Average Diluted Shares Outstanding		 112.80M 113.50M 114M 113.90M 113.40M 113.70M 115.10M 115.40M 116.20M 115.10M 111.20M
Weighted Average Basic & Diluted Shares Outstanding		 108.90M 109.33M 109.71M 108.56M 108.95M 109.76M 110.19M 110.23M 109.89M 109.32M 107.97M

Annual Cash Flow Statements for Regeneron Pharmaceuticals

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 160 -261 278 655 150 577 691 221 -382 -249
Net Cash From Operating Activities		 1,331 1,486 1,307 2,195 2,430 2,618 7,081 5,015 4,594 4,421
Net Cash From Continuing Operating Activities		 1,331 1,486 1,307 2,195 2,430 2,618 7,081 5,015 4,594 4,421
Net Income / (Loss) Continuing Operations		 636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413
Consolidated Net Income / (Loss)		 636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413
Depreciation Expense		 75 105 146 148 210 236 286 341 421 483
Non-Cash Adjustments To Reconcile Net Income		 512 605 571 440 435 297 783 1,325 1,151 901
Changes in Operating Assets and Liabilities, net		 108 -119 -608 -837 -331 -1,428 -2,064 -990 -932 -1,376
Net Cash From Investing Activities		 -908 -1,047 -1,005 -1,463 -2,028 -71 -5,385 -3,785 -3,185 -2,468
Net Cash From Continuing Investing Activities		 -908 -1,047 -1,005 -1,463 -2,028 -71 -5,385 -3,785 -3,185 -2,468
Purchase of Property, Plant & Equipment		 -678 -512 -273 -383 -430 -615 -552 -590 -719 -756
Acquisitions		 - - - - - 0.00 0.00 -230 -55 -17
Purchase of Investments		 -557 -809 -1,277 -1,846 -3,202 -3,241 -7,048 -7,488 -11,646 -16,617
Sale of Property, Plant & Equipment		 - - - - - - - 0.00 0.00 20
Sale and/or Maturity of Investments		 327 275 545 776 1,604 3,785 2,215 5,551 9,442 15,027
Other Investing Activities, net		 - 0.00 0.00 -10 - 0.00 0.00 -1,027 -208 -126
Net Cash From Financing Activities		 -263 -701 -24 -77 -252 -1,971 -1,006 -1,009 -1,790 -2,201
Net Cash From Continuing Financing Activities		 -263 -701 -24 -77 -252 -1,971 -1,006 -1,009 -1,790 -2,201
Repayment of Debt		 -168 -46 -20 0.00 0.00 -1,500 - 0.00 0.00 -33
Repurchase of Common Equity		 -573 -643 0.00 -4.40 -276 -5,847 -1,645 -2,083 -2,235 -2,603
Issuance of Common Equity		 206 127 240 115 212 2,575 1,672 1,520 1,146 1,465
Other Financing Activities, net		 245 -143 -302 -187 -188 -681 -1,033 -446 -701 -1,029
Effect of Exchange Rate Changes		 - - - - - - 0.00 0.00 -0.40 -0.70
Cash Interest Paid		 11 5.50 19 22 25 23 56 54 73 53
Cash Income Taxes Paid		 276 481 755 206 342 188 1,218 1,502 870 743

Quarterly Cash Flow Statements for Regeneron Pharmaceuticals

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Change in Cash & Equivalents		 96 -385 809 -1,979 211 578 -128 -682 84 477 604
Net Cash From Operating Activities		 629 1,720 1,368 1,022 1,114 1,090 1,513 354 1,291 1,263 1,045
Net Cash From Continuing Operating Activities		 629 1,720 1,368 1,022 1,114 1,090 1,513 354 1,291 1,263 1,045
Net Income / (Loss) Continuing Operations		 1,316 1,197 818 968 1,008 1,160 722 1,432 1,341 918 809
Consolidated Net Income / (Loss)		 1,316 1,197 818 968 1,008 1,160 722 1,432 1,341 918 809
Depreciation Expense		 93 100 100 103 105 113 114 121 122 126 127
Non-Cash Adjustments To Reconcile Net Income		 -27 320 426 242 319 165 426 -172 61 585 119
Changes in Operating Assets and Liabilities, net		 -753 102 24 -291 -318 -348 250 -1,027 -233 -367 -9.50
Net Cash From Investing Activities		 192 -1,858 -236 -2,387 -496 -66 -1,687 -557 -574 351 648
Net Cash From Continuing Investing Activities		 192 -1,858 -236 -2,387 -496 -66 -1,687 -557 -574 351 648
Purchase of Property, Plant & Equipment		 -143 -152 -178 -113 -176 -251 -134 -181 -242 -200 -229
Purchase of Investments		 -570 -3,143 -1,749 -4,522 -3,243 -2,132 -5,658 -4,416 -4,591 -1,953 -2,539
Sale and/or Maturity of Investments		 1,832 1,537 1,793 2,269 2,998 2,383 4,132 4,055 4,259 2,582 3,458
Other Investing Activities, net		 -927 -100 -101 -21 -24 -62 -28 -30 - -67 -42
Net Cash From Financing Activities		 -725 -248 -323 -614 -407 -446 47 -478 -634 -1,136 -1,089
Net Cash From Continuing Financing Activities		 -725 -248 -323 -614 -407 -446 47 -478 -634 -1,136 -1,089
Repayment of Debt		 - - - - - - - - - - -10
Repurchase of Common Equity		 -935 -431 -711 -689 -547 -289 -291 -604 -735 -973 -1,041
Payment of Dividends		 - - - - - - - - - - -94
Issuance of Common Equity		 319 373 485 91 269 301 682 438 255 91 61
Other Financing Activities, net		 -109 -189 -97 -16 -129 -458 -344 -312 -120 -253 -4.30
Effect of Exchange Rate Changes		 - - 0.00 -0.40 -0.20 0.20 -0.50 -0.30 0.80 -0.70 0.60

Annual Balance Sheets for Regeneron Pharmaceuticals

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 5,609 6,973 8,764 11,735 14,805 17,163 25,435 29,215 33,080 37,759
Total Current Assets		 2,915 3,180 4,335 6,448 7,689 9,779 14,015 15,884 19,479 18,661
Cash & Equivalents		 809 535 813 1,468 1,618 2,194 2,886 3,106 2,730 2,488
Short-Term Investments		 236 503 597 1,342 1,597 1,393 2,809 4,636 8,115 6,524
Accounts Receivable		 1,468 1,612 1,974 2,243 2,786 4,115 6,037 5,329 5,667 6,212
Inventories, net		 239 399 726 1,151 1,416 1,917 1,951 2,402 2,581 3,087
Prepaid Expenses		 164 131 225 243 274 161 332 411 387 349
Plant, Property, & Equipment, net		 1,594 2,083 2,359 2,576 0.00 0.00 3,482 3,763 4,146 4,600
Total Noncurrent Assets		 1,100 1,710 2,071 2,711 7,116 7,384 7,938 9,567 9,455 14,499
Long-Term Investments		 632 864 1,487 1,755 3,257 3,136 6,838 6,592 5,397 8,900
Intangible Assets		 - - - - - - 6.70 916 1,039 1,149
Noncurrent Deferred & Refundable Income Taxes		 462 825 506 829 824 859 877 1,724 2,575 3,314
Other Noncurrent Operating Assets		 5.81 20 78 127 3,035 3,390 216 336 444 1,136
Total Liabilities & Shareholders' Equity		 5,609 6,973 8,764 11,735 14,805 17,163 25,435 29,215 33,080 37,759
Total Liabilities		 1,954 2,524 2,620 2,977 3,716 6,138 6,666 6,551 7,107 8,406
Total Current Liabilities		 811 1,241 1,136 1,443 2,097 2,697 3,933 3,141 3,423 3,944
Accounts Payable		 644 879 178 218 418 476 564 589 607 790
Accrued Expenses		 - - 637 772 1,211 1,644 2,207 2,074 2,358 2,527
Current Deferred Revenue		 153 232 320 453 382 578 442 478 459 628
Total Noncurrent Liabilities		 1,143 1,283 1,485 1,534 1,619 3,441 2,734 3,409 3,684 4,462
Long-Term Debt		 - - - - 0.00 1,979 1,980 1,981 1,983 1,984
Capital Lease Obligations		 363 352 704 709 714 717 - 720 720 720
Noncurrent Deferred Revenue		 665 831 629 464 105 58 73 70 127 186
Other Noncurrent Operating Liabilities		 116 100 152 362 800 687 680 638 854 1,571
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354
Total Preferred & Common Equity		 3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354
Common Stock		 3,100 3,030 3,513 3,912 4,429 6,716 8,088 9,949 11,354 12,856
Retained Earnings		 853 1,748 2,947 5,254 7,380 10,893 18,968 23,307 27,260 31,673
Treasury Stock		 -306 -316 -316 -396 -740 -6,613 -8,261 -10,353 -12,560 -15,167
Accumulated Other Comprehensive Income / (Loss)		 8.57 -13 0.60 -12 21 29 -26 -239 -81 -7.90

Quarterly Balance Sheets for Regeneron Pharmaceuticals

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Total Assets		 27,678 29,215 30,060 30,658 32,163 33,080 34,370 36,087 37,442 37,759 37,545
Total Current Assets		 15,429 15,884 16,909 16,923 18,635 19,479 18,872 19,082 19,334 18,661 17,572
Cash & Equivalents		 3,491 3,106 3,916 1,937 2,152 2,730 2,602 1,921 2,012 2,488 3,090
Short-Term Investments		 3,530 4,636 5,043 6,991 7,761 8,115 7,918 7,888 7,785 6,524 5,259
Accounts Receivable		 5,548 5,329 5,119 5,121 5,585 5,667 5,222 5,717 6,107 6,212 5,561
Inventories, net		 2,412 2,402 2,425 2,508 2,562 2,581 2,715 2,874 3,018 3,087 3,192
Prepaid Expenses		 446 411 406 366 575 387 415 682 412 349 469
Plant, Property, & Equipment, net		 3,704 3,763 3,881 3,923 4,006 4,146 4,226 4,306 4,439 4,600 4,694
Total Noncurrent Assets		 8,545 9,567 9,270 9,812 9,522 9,455 11,273 12,699 13,669 14,499 15,279
Long-Term Investments		 5,969 6,592 6,067 6,327 5,779 5,397 6,979 7,722 8,491 8,900 9,276
Intangible Assets		 804 916 929 953 1,017 1,039 1,059 1,102 1,120 1,149 1,167
Noncurrent Deferred & Refundable Income Taxes		 1,452 1,724 1,925 2,139 2,317 2,575 2,765 2,881 3,015 3,314 3,443
Other Noncurrent Operating Assets		 320 336 350 393 410 444 470 994 1,043 1,136 1,393
Total Liabilities & Shareholders' Equity		 27,678 29,215 30,060 30,658 32,163 33,080 34,370 36,087 37,442 37,759 37,545
Total Liabilities		 6,239 6,551 6,565 6,640 7,259 7,107 7,379 7,881 8,116 8,406 8,158
Total Current Liabilities		 2,879 3,141 3,100 3,104 3,599 3,423 3,581 3,509 3,661 3,944 3,567
Accounts Payable		 536 589 600 547 537 607 671 562 497 790 706
Accrued Expenses		 1,796 2,074 2,074 2,176 2,645 2,358 2,393 2,361 2,537 2,527 2,242
Current Deferred Revenue		 547 478 426 381 417 459 517 586 627 628 619
Total Noncurrent Liabilities		 3,360 3,409 3,465 3,535 3,660 3,684 3,798 4,372 4,455 4,462 4,591
Long-Term Debt		 1,981 1,981 1,982 1,982 1,983 1,983 1,983 1,984 1,984 1,984 1,985
Capital Lease Obligations		 720 720 720 720 720 720 720 720 720 720 720
Noncurrent Deferred Revenue		 60 70 86 116 125 127 186 206 207 186 212
Other Noncurrent Operating Liabilities		 599 638 677 717 832 854 909 1,463 1,544 1,571 1,674
Total Equity & Noncontrolling Interests		 21,439 22,664 23,495 24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388
Total Preferred & Common Equity		 21,439 22,664 23,495 24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 21,439 22,664 23,495 24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388
Common Stock		 9,518 9,949 10,598 10,889 11,252 11,354 11,943 12,317 12,703 12,856 13,192
Retained Earnings		 22,110 23,307 24,125 25,093 26,101 27,260 27,982 29,415 30,755 31,673 32,384
Treasury Stock		 -9,914 -10,353 -11,046 -11,766 -12,271 -12,560 -12,857 -13,456 -14,192 -15,167 -16,218
Accumulated Other Comprehensive Income / (Loss)		 -275 -239 -182 -198 -177 -81 -77 -70 60 -7.90 29

Annual Metrics and Ratios for Regeneron Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 45.55% 18.44% 20.82% -12.37% 27.44% 29.58% 89.14% -24.26% 7.76% 8.27%
EBITDA Growth		 54.38% 9.63% 56.10% 21.38% -2.21% 53.70% 135.65% -45.61% -10.77% 13.31%
EBIT Growth		 55.19% 7.81% 57.44% 22.73% -4.74% 57.25% 142.63% -47.58% -13.13% 13.17%
NOPAT Growth		 77.61% 37.87% 33.82% 102.32% -20.66% 71.32% 134.93% -45.38% -9.95% -3.31%
Net Income Growth		 88.11% 40.79% 33.84% 103.95% -13.44% 66.05% 129.86% -46.28% -8.87% 11.61%
EPS Growth		 85.23% 39.49% 34.29% 105.90% -13.29% 65.33% 135.81% -46.89% -9.03% 10.27%
Operating Cash Flow Growth		 76.86% 11.66% -12.03% 67.94% 10.70% 7.74% 170.47% -29.18% -8.39% -3.78%
Free Cash Flow Firm Growth		 -147.11% 585.45% 31.53% 437.10% 1.11% 9.28% 300.15% -78.31% 69.96% -18.01%
Invested Capital Growth		 42.07% 29.36% 30.53% 24.02% 8.81% 31.24% 17.40% 34.26% 12.72% 13.76%
Revenue Q/Q Growth		 7.77% 2.72% 6.45% -19.16% 29.68% 7.05% 18.67% -11.21% 0.15% 2.56%
EBITDA Q/Q Growth		 5.54% 7.77% 11.01% 5.04% 9.18% 9.33% 15.41% -17.94% -3.36% -3.34%
EBIT Q/Q Growth		 5.11% 7.91% 11.52% 5.00% 9.48% 9.73% 15.77% -19.29% -3.96% -3.92%
NOPAT Q/Q Growth		 9.28% 12.45% -7.29% 39.38% -11.70% 17.71% 19.23% -23.67% -1.02% -1.01%
Net Income Q/Q Growth		 11.36% 12.30% -6.23% 35.98% -1.32% 11.32% 15.44% -19.21% -0.94% -5.20%
EPS Q/Q Growth		 11.29% 11.59% -5.74% 35.86% -1.12% 11.55% 15.19% -19.23% -0.77% -5.17%
Operating Cash Flow Q/Q Growth		 6.71% 7.88% 15.62% 7.96% 2.47% 20.40% 19.22% -11.51% -12.06% 4.08%
Free Cash Flow Firm Q/Q Growth		 -142.44% -65.54% 161.21% 15.51% 2.07% -10.61% 33.76% -35.99% -21.96% 4.19%
Invested Capital Q/Q Growth		 10.67% 31.34% -2.37% 8.67% 2.03% 12.83% 5.08% -1.06% 4.36% 2.93%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 90.43% 93.83% 93.24% 91.89% 88.33% 86.82% 84.83% 87.18% 86.16% 86.13%
EBITDA Margin		 32.03% 29.64% 38.30% 53.05% 40.71% 48.29% 60.16% 43.21% 35.78% 37.45%
Operating Margin		 30.51% 27.38% 35.41% 49.25% 33.70% 42.09% 55.67% 38.93% 30.85% 28.10%
EBIT Margin		 30.20% 27.49% 35.82% 50.17% 37.50% 45.51% 58.38% 40.40% 32.57% 34.05%
Profit (Net Income) Margin		 15.50% 18.42% 20.41% 47.50% 32.26% 41.35% 50.25% 35.64% 30.14% 31.07%
Tax Burden Percent		 51.92% 67.34% 57.66% 95.73% 87.10% 92.20% 86.59% 89.29% 94.15% 92.32%
Interest Burden Percent		 98.85% 99.53% 98.81% 98.91% 98.77% 98.53% 99.39% 98.79% 98.29% 98.86%
Effective Tax Rate		 48.08% 32.66% 42.34% 4.27% 12.90% 7.80% 13.41% 10.71% 5.85% 7.68%
Return on Invested Capital (ROIC)		 32.60% 33.39% 34.36% 54.81% 37.62% 53.49% 101.84% 43.97% 32.48% 27.72%
ROIC Less NNEP Spread (ROIC-NNEP)		 33.86% 33.43% 34.40% 54.21% 33.64% 49.08% 97.34% 43.00% 31.34% 22.65%
Return on Net Nonoperating Assets (RNNOA)		 -12.10% -11.29% -11.74% -22.00% -16.30% -21.71% -47.63% -23.03% -16.22% -11.77%
Return on Equity (ROE)		 20.50% 22.10% 22.63% 32.81% 21.32% 31.77% 54.21% 20.94% 16.26% 15.95%
Cash Return on Invested Capital (CROIC)		 -2.16% 7.79% 7.88% 33.36% 29.18% 26.47% 85.83% 14.72% 20.51% 14.85%
Operating Return on Assets (OROA)		 26.24% 21.24% 26.73% 25.19% 18.53% 24.19% 44.05% 18.00% 13.72% 13.65%
Return on Assets (ROA)		 13.47% 14.23% 15.23% 23.85% 15.94% 21.98% 37.91% 15.88% 12.69% 12.46%
Return on Common Equity (ROCE)		 20.50% 22.10% 22.63% 32.81% 21.32% 31.77% 54.21% 20.94% 16.26% 15.95%
Return on Equity Simple (ROE_SIMPLE)		 17.40% 20.13% 19.51% 27.91% 19.08% 31.86% 43.03% 19.14% 15.22% 15.03%
Net Operating Profit after Tax (NOPAT)		 650 896 1,199 2,426 1,925 3,298 7,747 4,231 3,810 3,684
NOPAT Margin		 15.84% 18.44% 20.42% 47.15% 29.35% 38.81% 48.20% 34.76% 29.05% 25.94%
Net Nonoperating Expense Percent (NNEP)		 -1.26% -0.04% -0.04% 0.60% 3.97% 4.41% 4.50% 0.97% 1.14% 5.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 16.68% 13.29% 11.49%
Cost of Revenue to Revenue		 9.57% 6.17% 6.76% 8.11% 11.67% 13.18% 15.17% 12.82% 13.84% 13.87%
SG&A Expenses to Revenue		 20.43% 24.23% 22.49% 21.91% 20.46% 15.84% 11.35% 17.38% 20.06% 20.80%
R&D to Revenue		 39.49% 42.22% 35.34% 28.54% 37.36% 32.19% 18.09% 31.61% 35.26% 36.85%
Operating Expenses to Revenue		 59.92% 66.46% 57.82% 42.63% 54.63% 44.73% 29.17% 48.25% 55.30% 58.03%
Earnings before Interest and Taxes (EBIT)		 1,239 1,336 2,104 2,582 2,459 3,867 9,383 4,918 4,272 4,835
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1,314 1,441 2,249 2,730 2,670 4,103 9,669 5,260 4,693 5,318
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 15.46 8.70 6.57 4.62 3.72 4.68 3.62 3.47 3.68 2.67
Price to Tangible Book Value (P/TBV)		 15.46 8.70 6.57 4.62 3.72 4.68 3.62 3.61 3.84 2.78
Price to Revenue (P/Rev)		 13.77 7.97 6.88 7.86 6.29 6.07 4.23 6.45 7.29 5.51
Price to Earnings (P/E)		 88.82 43.24 33.70 16.54 19.48 14.67 8.41 18.11 24.20 17.74
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.13% 2.31% 2.97% 6.05% 5.13% 6.82% 11.89% 5.52% 4.13% 5.64%
Enterprise Value to Invested Capital (EV/IC)		 23.58 12.32 9.67 7.46 6.65 6.79 6.98 6.07 6.61 4.46
Enterprise Value to Revenue (EV/Rev)		 13.45 7.67 6.51 7.11 5.41 5.59 3.57 5.50 6.26 4.44
Enterprise Value to EBITDA (EV/EBITDA)		 41.99 25.89 16.98 13.40 13.29 11.58 5.93 12.73 17.50 11.86
Enterprise Value to EBIT (EV/EBIT)		 44.52 27.91 18.16 14.16 14.42 12.29 6.11 13.61 19.23 13.04
Enterprise Value to NOPAT (EV/NOPAT)		 84.89 41.62 31.86 15.07 18.43 14.41 7.40 15.82 21.56 17.12
Enterprise Value to Operating Cash Flow (EV/OCF)		 41.46 25.10 29.23 16.66 14.60 18.15 8.10 13.35 17.88 14.27
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 178.40 138.93 24.76 23.75 29.12 8.79 47.27 34.13 31.96
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.10 0.11 0.11 0.08 0.06 0.24 0.11 0.12 0.10 0.09
Long-Term Debt to Equity		 0.10 0.08 0.11 0.08 0.06 0.24 0.11 0.12 0.10 0.09
Financial Leverage		 -0.36 -0.34 -0.34 -0.41 -0.48 -0.44 -0.49 -0.54 -0.52 -0.52
Leverage Ratio		 1.52 1.55 1.49 1.38 1.34 1.45 1.43 1.32 1.28 1.28
Compound Leverage Factor		 1.50 1.55 1.47 1.36 1.32 1.42 1.42 1.30 1.26 1.27
Debt to Total Capital		 9.03% 9.76% 10.27% 7.48% 6.05% 19.65% 9.54% 10.65% 9.43% 8.44%
Short-Term Debt to Total Capital		 0.00% 2.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.03% 7.13% 10.27% 7.48% 6.05% 19.65% 9.54% 10.65% 9.43% 8.44%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 90.97% 90.24% 89.73% 92.51% 93.95% 80.35% 90.46% 89.35% 90.57% 91.56%
Debt to EBITDA		 0.28 0.33 0.31 0.26 0.27 0.66 0.20 0.51 0.58 0.51
Net Debt to EBITDA		 -1.00 -0.99 -0.97 -1.41 -2.16 -0.98 -1.09 -2.21 -2.88 -2.86
Long-Term Debt to EBITDA		 0.28 0.24 0.31 0.26 0.27 0.66 0.20 0.51 0.58 0.51
Debt to NOPAT		 0.56 0.54 0.59 0.29 0.37 0.82 0.26 0.64 0.71 0.73
Net Debt to NOPAT		 -2.02 -1.59 -1.83 -1.59 -2.99 -1.22 -1.36 -2.75 -3.55 -4.13
Long-Term Debt to NOPAT		 0.56 0.39 0.59 0.29 0.37 0.82 0.26 0.64 0.71 0.73
Altman Z-Score		 19.47 11.22 11.62 10.45 8.80 7.66 9.48 9.81 10.64 8.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.59 2.56 3.82 4.47 3.67 3.63 3.56 5.06 5.69 4.73
Quick Ratio		 3.10 2.13 2.98 3.50 2.86 2.86 2.98 4.16 4.82 3.86
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -43 209 275 1,477 1,493 1,632 6,529 1,416 2,407 1,973
Operating Cash Flow to CapEx		 196.30% 290.27% 479.49% 572.98% 565.64% 425.98% 1,283.08% 849.84% 639.30% 600.77%
Free Cash Flow to Firm to Interest Expense		 0.00 29.03 10.95 52.37 49.44 28.68 113.95 23.84 32.97 35.75
Operating Cash Flow to Interest Expense		 0.00 206.38 52.08 77.84 80.46 46.01 123.58 84.43 62.93 80.08
Operating Cash Flow Less CapEx to Interest Expense		 0.00 135.28 41.22 64.26 66.24 35.21 113.95 74.49 53.09 66.75
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.87 0.77 0.75 0.50 0.49 0.53 0.75 0.45 0.42 0.40
Accounts Receivable Turnover		 3.36 3.16 3.28 2.44 2.61 2.46 3.17 2.14 2.39 2.39
Inventory Turnover		 2.14 0.94 0.71 0.44 0.60 0.67 1.26 0.72 0.73 0.70
Fixed Asset Turnover		 3.20 2.64 2.64 2.09 0.00 0.00 0.00 3.36 3.32 3.25
Accounts Payable Turnover		 0.70 0.39 0.75 2.11 2.40 2.51 4.69 2.71 3.04 2.82
Days Sales Outstanding (DSO)		 108.70 115.63 111.45 149.58 139.95 148.20 115.27 170.39 152.99 152.65
Days Inventory Outstanding (DIO)		 170.76 388.47 517.24 820.62 612.24 543.00 289.60 509.14 500.76 524.93
Days Payable Outstanding (DPO)		 524.02 927.55 485.91 173.28 151.78 145.62 77.83 134.88 120.19 129.30
Cash Conversion Cycle (CCC)		 -244.57 -423.45 142.77 796.92 600.41 545.58 327.04 544.65 533.57 548.28
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2,340 3,027 3,952 4,901 5,333 6,998 8,216 11,031 12,435 14,145
Invested Capital Turnover		 2.06 1.81 1.68 1.16 1.28 1.38 2.11 1.26 1.12 1.07
Increase / (Decrease) in Invested Capital		 693 687 924 949 432 1,666 1,218 2,815 1,403 1,711
Enterprise Value (EV)		 55,179 37,295 38,200 36,569 35,469 47,524 57,363 66,939 82,149 63,069
Market Capitalization		 56,494 38,717 40,393 40,426 41,226 51,551 67,916 78,572 95,687 78,278
Book Value per Share		 $35.12 $42.18 $57.19 $80.91 $101.00 $103.32 $174.52 $208.11 $238.40 $267.12
Tangible Book Value per Share		 $35.12 $42.18 $57.19 $80.91 $101.00 $103.32 $174.46 $199.71 $228.87 $256.67
Total Capital		 4,018 4,930 6,848 9,466 11,804 13,721 20,749 25,366 28,676 32,058
Total Debt		 363 481 704 709 714 2,696 1,980 2,701 2,703 2,704
Total Long-Term Debt		 363 352 704 709 714 2,696 1,980 2,701 2,703 2,704
Net Debt		 -1,314 -1,422 -2,193 -3,856 -5,757 -4,027 -10,553 -11,633 -13,538 -15,208
Capital Expenditures (CapEx)		 678 512 273 383 430 615 552 590 719 736
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,059 1,030 1,790 2,195 2,378 3,495 4,388 5,001 5,211 5,704
Debt-free Net Working Capital (DFNWC)		 2,104 2,068 3,200 5,005 5,593 7,082 10,082 12,743 16,056 14,717
Net Working Capital (NWC)		 2,104 1,939 3,200 5,005 5,593 7,082 10,082 12,743 16,056 14,717
Net Nonoperating Expense (NNE)		 14 0.61 0.63 -18 -191 -216 -328 -107 -143 -729
Net Nonoperating Obligations (NNO)		 -1,314 -1,422 -2,193 -3,856 -5,757 -4,027 -10,553 -11,633 -13,538 -15,208
Total Depreciation and Amortization (D&A)		 75 105 146 148 210 236 286 341 421 483
Debt-free, Cash-free Net Working Capital to Revenue		 25.80% 21.18% 30.48% 42.66% 36.27% 41.13% 27.30% 41.08% 39.73% 40.16%
Debt-free Net Working Capital to Revenue		 51.27% 42.55% 54.49% 97.26% 85.28% 83.34% 62.73% 104.68% 122.40% 103.62%
Net Working Capital to Revenue		 51.27% 39.89% 54.49% 97.26% 85.28% 83.34% 62.73% 104.68% 122.40% 103.62%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $6.17 $8.55 $11.27 $22.65 $19.38 $32.65 $76.40 $40.51 $37.05 $40.90
Adjusted Weighted Average Basic Shares Outstanding		 103.06M 104.72M 106.34M 107.90M 109.20M 107.60M 105.70M 107.10M 106.70M 107.90M
Adjusted Diluted Earnings per Share		 $5.52 $7.70 $10.34 $21.29 $18.46 $30.52 $71.97 $38.22 $34.77 $38.34
Adjusted Weighted Average Diluted Shares Outstanding		 115.23M 116.37M 115.95M 114.80M 114.60M 115.10M 112.20M 113.50M 113.70M 115.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $19.38 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 104.79M 106.08M 107.70M 109.28M 110.02M 107.13M 108.54M 109.33M 109.76M 109.32M
Normalized Net Operating Profit after Tax (NOPAT)		 650 896 1,199 2,426 1,925 3,298 7,747 4,231 3,810 3,684
Normalized NOPAT Margin		 15.84% 18.44% 20.42% 47.15% 29.35% 38.81% 48.20% 34.76% 29.05% 25.94%
Pre Tax Income Margin		 29.85% 27.36% 35.40% 49.62% 37.04% 44.84% 58.03% 39.91% 32.01% 33.66%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 185.57 83.81 91.55 81.43 67.97 163.75 82.80 58.52 87.59
NOPAT to Interest Expense		 0.00 124.46 47.77 86.03 63.73 57.95 135.20 71.23 52.20 66.74
EBIT Less CapEx to Interest Expense		 0.00 114.47 72.95 77.96 67.21 57.17 154.12 72.86 48.68 74.26
NOPAT Less CapEx to Interest Expense		 0.00 53.36 36.91 72.45 49.51 47.15 125.57 61.30 42.35 53.41
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 90.16% 71.85% 0.00% 0.18% 13.04% 166.42% 20.38% 48.01% 56.53% 59.00%

Quarterly Metrics and Ratios for Regeneron Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -14.96% -31.05% 6.64% 10.53% 14.53% 0.58% -0.54% 12.32% 10.65% 10.33% -3.70%
EBITDA Growth		 -15.04% -44.36% -15.10% 14.68% -23.72% -11.32% -14.82% 46.37% 31.97% -14.38% 25.24%
EBIT Growth		 -16.70% -46.69% -18.49% 12.85% -26.00% -13.13% -18.17% 49.11% 33.51% -16.92% 27.47%
NOPAT Growth		 -35.75% -55.91% -21.85% -7.42% -5.48% -5.14% -14.20% 3.51% 5.07% -3.52% -31.71%
Net Income Growth		 -19.39% -46.29% -15.99% 13.65% -23.40% -3.13% -11.71% 47.90% 33.02% -20.86% 12.01%
EPS Growth		 -18.63% -46.48% -16.72% 13.79% -23.76% -2.58% -12.55% 46.00% 29.81% -20.47% 15.95%
Operating Cash Flow Growth		 -81.58% -27.51% -34.93% 81.15% 77.18% -36.64% 10.60% -65.38% 15.88% 15.89% -30.90%
Free Cash Flow Firm Growth		 -5,270.86% -257.05% -328.23% -232.02% 110.72% 76.37% 85.95% 15.49% -416.67% -81.35% -593.53%
Invested Capital Growth		 42.60% 34.26% 31.72% 21.89% 6.86% 12.72% 9.18% 16.68% 15.34% 13.76% 18.62%
Revenue Q/Q Growth		 2.76% 16.29% -7.39% -0.13% 6.48% 2.13% -8.42% 12.79% 4.89% 1.84% -20.07%
EBITDA Q/Q Growth		 53.96% -10.85% -32.36% 23.52% 2.42% 3.64% -35.03% 112.25% -7.66% -32.76% -4.97%
EBIT Q/Q Growth		 56.21% -12.00% -34.73% 25.78% 2.43% 3.31% -38.52% 129.20% -8.28% -35.72% -5.67%
NOPAT Q/Q Growth		 8.61% -2.82% -12.93% 0.74% 10.89% -2.47% -21.24% 21.53% 12.55% -10.45% -44.25%
Net Income Q/Q Growth		 54.41% -9.01% -31.68% 18.42% 4.07% 15.06% -37.74% 98.38% -6.40% -31.55% -11.88%
EPS Q/Q Growth		 56.09% -10.12% -31.58% 18.55% 4.59% 14.85% -38.59% 97.93% -7.01% -29.64% -10.47%
Operating Cash Flow Q/Q Growth		 11.43% 173.48% -20.48% -25.24% 8.99% -2.21% 38.80% -76.60% 264.75% -2.20% -17.24%
Free Cash Flow Firm Q/Q Growth		 -359.97% 21.45% -0.51% 35.68% 121.10% -273.20% 40.25% -286.94% 20.92% 0.81% -128.51%
Invested Capital Q/Q Growth		 18.53% -1.06% 1.26% 2.64% 3.92% 4.36% -1.92% 9.69% 2.72% 2.93% 2.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.18% 84.17% 85.53% 87.18% 87.02% 84.95% 86.21% 86.46% 86.80% 85.08% 84.67%
EBITDA Margin		 55.10% 42.24% 30.85% 38.15% 36.70% 37.24% 26.42% 49.72% 43.77% 28.90% 34.36%
Operating Margin		 41.68% 33.59% 29.94% 32.19% 33.04% 28.33% 23.89% 30.15% 31.70% 26.13% 19.54%
EBIT Margin		 51.94% 39.31% 27.70% 34.89% 33.56% 33.95% 22.79% 46.32% 40.50% 25.56% 30.17%
Profit (Net Income) Margin		 44.81% 35.06% 25.86% 30.66% 29.97% 33.77% 22.96% 40.38% 36.03% 24.22% 26.70%
Tax Burden Percent		 87.14% 90.37% 95.31% 89.43% 90.73% 101.05% 103.04% 87.97% 89.79% 95.78% 89.36%
Interest Burden Percent		 99.00% 98.70% 97.95% 98.28% 98.42% 98.43% 97.75% 99.10% 99.08% 98.92% 99.05%
Effective Tax Rate		 12.86% 9.63% 4.69% 10.57% 9.27% -1.05% -3.04% 12.03% 10.21% 4.22% 10.64%
Return on Invested Capital (ROIC)		 52.50% 38.39% 35.93% 34.95% 34.04% 32.00% 27.60% 28.81% 30.72% 26.75% 18.45%
ROIC Less NNEP Spread (ROIC-NNEP)		 49.97% 36.94% 36.64% 34.45% 34.04% 30.60% 27.99% 25.22% 28.75% 26.96% 16.56%
Return on Net Nonoperating Assets (RNNOA)		 -25.48% -19.78% -20.05% -18.37% -17.10% -15.84% -15.03% -13.22% -15.15% -14.01% -8.73%
Return on Equity (ROE)		 27.02% 18.61% 15.87% 16.58% 16.94% 16.17% 12.57% 15.59% 15.57% 12.74% 9.72%
Cash Return on Invested Capital (CROIC)		 23.33% 14.72% 13.10% 17.65% 26.74% 20.51% 22.69% 14.22% 14.76% 14.85% 8.91%
Operating Return on Assets (OROA)		 27.74% 17.51% 12.15% 15.28% 14.69% 14.30% 9.27% 18.72% 16.11% 10.25% 11.82%
Return on Assets (ROA)		 23.93% 15.62% 11.34% 13.43% 13.12% 14.22% 9.34% 16.32% 14.34% 9.71% 10.46%
Return on Common Equity (ROCE)		 27.02% 18.61% 15.87% 16.58% 16.94% 16.17% 12.57% 15.59% 15.57% 12.74% 9.72%
Return on Equity Simple (ROE_SIMPLE)		 25.05% 0.00% 17.80% 17.90% 16.03% 0.00% 14.29% 15.32% 15.87% 0.00% 15.31%
Net Operating Profit after Tax (NOPAT)		 1,066 1,036 902 909 1,008 983 774 941 1,059 948 529
NOPAT Margin		 36.32% 30.35% 28.54% 28.78% 29.98% 28.63% 24.62% 26.53% 28.47% 25.03% 17.46%
Net Nonoperating Expense Percent (NNEP)		 2.53% 1.45% -0.71% 0.50% 0.00% 1.40% -0.39% 3.59% 1.97% -0.21% 1.88%
Return On Investment Capital (ROIC_SIMPLE)		 - 4.09% - - - 3.43% - - - 2.96% 1.65%
Cost of Revenue to Revenue		 10.82% 15.83% 14.47% 12.82% 12.98% 15.05% 13.79% 13.54% 13.20% 14.92% 15.33%
SG&A Expenses to Revenue		 18.02% 19.34% 19.01% 20.65% 19.05% 21.48% 21.91% 21.39% 19.20% 20.91% 20.90%
R&D to Revenue		 31.04% 31.43% 36.60% 34.37% 34.95% 35.15% 39.92% 34.50% 35.68% 37.63% 44.23%
Operating Expenses to Revenue		 47.50% 50.58% 55.59% 54.99% 53.98% 56.62% 62.31% 56.31% 55.10% 58.95% 65.13%
Earnings before Interest and Taxes (EBIT)		 1,525 1,342 876 1,102 1,129 1,166 717 1,643 1,507 969 914
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1,618 1,442 976 1,205 1,234 1,279 831 1,764 1,629 1,095 1,041
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.50 3.47 3.82 3.28 3.59 3.68 3.89 4.11 3.95 2.67 2.36
Price to Tangible Book Value (P/TBV)		 3.64 3.61 3.98 3.42 3.74 3.84 4.04 4.27 4.11 2.78 2.46
Price to Revenue (P/Rev)		 5.48 6.45 7.26 6.22 6.82 7.29 8.00 8.59 8.37 5.51 4.92
Price to Earnings (P/E)		 13.98 18.11 21.48 18.34 22.38 24.20 27.18 26.80 24.90 17.74 15.41
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.14%
Earnings Yield		 7.15% 5.52% 4.66% 5.45% 4.47% 4.13% 3.68% 3.73% 4.02% 5.64% 6.49%
Enterprise Value to Invested Capital (EV/IC)		 5.81 6.07 6.94 5.78 6.41 6.61 7.38 7.55 7.30 4.46 3.76
Enterprise Value to Revenue (EV/Rev)		 4.73 5.50 6.27 5.23 5.83 6.26 6.88 7.49 7.24 4.44 3.86
Enterprise Value to EBITDA (EV/EBITDA)		 10.11 12.73 15.24 12.65 15.72 17.50 19.80 19.77 18.23 11.86 9.84
Enterprise Value to EBIT (EV/EBIT)		 10.63 13.61 16.42 13.68 17.16 19.23 21.90 21.70 19.93 13.04 10.81
Enterprise Value to NOPAT (EV/NOPAT)		 11.69 15.82 19.49 16.99 19.83 21.56 24.50 27.45 26.95 17.12 15.74
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.43 13.35 18.11 13.99 14.61 17.88 19.01 24.81 23.61 14.27 13.77
Enterprise Value to Free Cash Flow (EV/FCFF)		 29.29 47.27 60.22 35.97 24.76 34.13 33.98 57.18 52.96 31.96 45.82
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.13 0.12 0.12 0.11 0.11 0.10 0.10 0.10 0.09 0.09 0.09
Long-Term Debt to Equity		 0.13 0.12 0.12 0.11 0.11 0.10 0.10 0.10 0.09 0.09 0.09
Financial Leverage		 -0.51 -0.54 -0.55 -0.53 -0.50 -0.52 -0.54 -0.52 -0.53 -0.52 -0.53
Leverage Ratio		 1.33 1.32 1.30 1.29 1.29 1.28 1.28 1.28 1.28 1.28 1.28
Compound Leverage Factor		 1.31 1.30 1.27 1.27 1.27 1.26 1.25 1.27 1.27 1.27 1.26
Debt to Total Capital		 11.19% 10.65% 10.31% 10.11% 9.79% 9.43% 9.10% 8.75% 8.44% 8.44% 8.43%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 11.19% 10.65% 10.31% 10.11% 9.79% 9.43% 9.10% 8.75% 8.44% 8.44% 8.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 88.81% 89.35% 89.69% 89.89% 90.21% 90.57% 90.90% 91.25% 91.56% 91.56% 91.57%
Debt to EBITDA		 0.42 0.51 0.53 0.52 0.56 0.58 0.59 0.53 0.49 0.51 0.49
Net Debt to EBITDA		 -1.61 -2.21 -2.42 -2.40 -2.67 -2.88 -3.25 -2.90 -2.83 -2.86 -2.70
Long-Term Debt to EBITDA		 0.42 0.51 0.53 0.52 0.56 0.58 0.59 0.53 0.49 0.51 0.49
Debt to NOPAT		 0.49 0.64 0.68 0.69 0.70 0.71 0.74 0.73 0.73 0.73 0.78
Net Debt to NOPAT		 -1.86 -2.75 -3.10 -3.22 -3.37 -3.55 -4.02 -4.03 -4.19 -4.13 -4.31
Long-Term Debt to NOPAT		 0.49 0.64 0.68 0.69 0.70 0.71 0.74 0.73 0.73 0.73 0.78
Altman Z-Score		 9.56 9.41 10.39 9.34 9.60 10.33 10.65 11.00 10.72 7.69 7.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.36 5.06 5.45 5.45 5.18 5.69 5.27 5.44 5.28 4.73 4.93
Quick Ratio		 4.37 4.16 4.54 4.53 4.31 4.82 4.40 4.43 4.34 3.86 3.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2,265 -1,779 -1,788 -1,150 243 -420 -251 -972 -768 -762 -1,742
Operating Cash Flow to CapEx		 441.33% 1,130.03% 767.45% 904.78% 633.13% 433.45% 1,129.57% 196.12% 533.77% 632.67% 455.78%
Free Cash Flow to Firm to Interest Expense		 -148.01 -102.23 -99.33 -60.85 13.63 -22.97 -15.60 -65.66 -55.69 -72.60 -200.21
Operating Cash Flow to Interest Expense		 41.10 98.84 75.98 54.10 62.60 59.55 93.94 23.92 93.57 120.27 120.13
Operating Cash Flow Less CapEx to Interest Expense		 31.79 90.10 66.08 48.12 52.71 45.81 85.63 11.72 76.04 101.26 93.77
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.53 0.45 0.44 0.44 0.44 0.42 0.41 0.40 0.40 0.40 0.39
Accounts Receivable Turnover		 2.49 2.14 2.48 2.46 2.35 2.39 2.53 2.49 2.37 2.39 2.61
Inventory Turnover		 0.90 0.72 0.73 0.73 0.74 0.73 0.70 0.69 0.69 0.70 0.68
Fixed Asset Turnover		 3.86 3.36 3.33 3.35 3.40 3.32 3.23 3.28 3.28 3.25 3.16
Accounts Payable Turnover		 4.16 2.71 3.02 3.18 3.43 3.04 2.82 3.37 3.72 2.82 2.91
Days Sales Outstanding (DSO)		 146.43 170.39 146.91 148.10 155.13 152.99 144.06 146.64 154.09 152.65 139.71
Days Inventory Outstanding (DIO)		 407.03 509.14 499.66 501.24 493.53 500.76 523.40 525.91 529.81 524.93 538.77
Days Payable Outstanding (DPO)		 87.73 134.88 121.04 114.70 106.38 120.19 129.41 108.38 98.17 129.30 125.57
Cash Conversion Cycle (CCC)		 465.73 544.65 525.53 534.64 542.27 533.57 538.04 564.17 585.74 548.28 552.91
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11,150 11,031 11,171 11,465 11,915 12,435 12,196 13,378 13,743 14,145 14,467
Invested Capital Turnover		 1.45 1.26 1.26 1.21 1.14 1.12 1.12 1.09 1.08 1.07 1.06
Increase / (Decrease) in Invested Capital		 3,331 2,815 2,690 2,059 765 1,403 1,025 1,913 1,828 1,711 2,271
Enterprise Value (EV)		 64,803 66,939 77,505 66,279 76,350 82,149 90,065 100,980 100,300 63,069 54,416
Market Capitalization		 75,093 78,572 89,830 78,831 89,339 95,687 104,860 115,808 115,883 78,278 69,337
Book Value per Share		 $196.67 $208.11 $214.91 $218.92 $229.41 $238.40 $250.38 $255.98 $266.03 $267.12 $268.81
Tangible Book Value per Share		 $189.29 $199.71 $206.42 $210.23 $220.04 $228.87 $240.56 $245.98 $255.87 $256.67 $258.14
Total Capital		 24,140 25,366 26,197 26,720 27,607 28,676 29,695 30,910 32,030 32,058 32,092
Total Debt		 2,701 2,701 2,702 2,702 2,703 2,703 2,703 2,704 2,704 2,704 2,705
Total Long-Term Debt		 2,701 2,701 2,702 2,702 2,703 2,703 2,703 2,704 2,704 2,704 2,705
Net Debt		 -10,289 -11,633 -12,325 -12,553 -12,990 -13,538 -14,795 -14,828 -15,583 -15,208 -14,921
Capital Expenditures (CapEx)		 143 152 178 113 176 251 134 181 242 200 229
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5,528 5,001 4,849 4,891 5,123 5,211 4,771 5,764 5,876 5,704 5,656
Debt-free Net Working Capital (DFNWC)		 12,549 12,743 13,809 13,819 15,036 16,056 15,291 15,573 15,673 14,717 14,005
Net Working Capital (NWC)		 12,549 12,743 13,809 13,819 15,036 16,056 15,291 15,573 15,673 14,717 14,005
Net Nonoperating Expense (NNE)		 -249 -161 85 -59 0.18 -177 52 -491 -281 31 -280
Net Nonoperating Obligations (NNO)		 -10,289 -11,633 -12,325 -12,553 -12,990 -13,538 -14,795 -14,828 -15,584 -15,208 -14,921
Total Depreciation and Amortization (D&A)		 93 100 100 103 105 113 114 121 122 126 127
Debt-free, Cash-free Net Working Capital to Revenue		 40.32% 41.08% 39.20% 38.60% 39.11% 39.73% 36.42% 42.73% 42.44% 40.16% 40.15%
Debt-free Net Working Capital to Revenue		 91.53% 104.68% 111.63% 109.06% 114.80% 122.40% 116.72% 115.45% 113.18% 103.62% 99.43%
Net Working Capital to Revenue		 91.53% 104.68% 111.63% 109.06% 114.80% 122.40% 116.72% 115.45% 113.18% 103.62% 99.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $12.31 $11.18 $7.64 $9.05 $9.48 $10.88 $6.70 $13.25 $12.40 $8.55 $7.58
Adjusted Weighted Average Basic Shares Outstanding		 106.90M 107.10M 107.10M 107M 106.30M 106.70M 107.80M 108.10M 108.10M 107.90M 106.70M
Adjusted Diluted Earnings per Share		 $11.66 $10.48 $7.17 $8.50 $8.89 $10.21 $6.27 $12.41 $11.54 $8.12 $7.27
Adjusted Weighted Average Diluted Shares Outstanding		 112.80M 113.50M 114M 113.90M 113.40M 113.70M 115.10M 115.40M 116.20M 115.10M 111.20M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 108.90M 109.33M 109.71M 108.56M 108.95M 109.76M 110.19M 110.23M 109.89M 109.32M 107.97M
Normalized Net Operating Profit after Tax (NOPAT)		 1,066 1,036 902 909 1,008 681 526 941 1,059 948 529
Normalized NOPAT Margin		 36.32% 30.35% 28.54% 28.78% 29.98% 19.83% 16.72% 26.53% 28.47% 25.03% 17.46%
Pre Tax Income Margin		 51.42% 38.80% 27.13% 34.29% 33.03% 33.42% 22.28% 45.90% 40.13% 25.29% 29.88%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 99.68 77.13 48.67 58.30 63.40 63.71 44.52 111.01 109.19 92.25 105.02
NOPAT to Interest Expense		 69.70 59.56 50.13 48.10 56.63 53.72 48.09 63.58 76.75 90.33 60.77
EBIT Less CapEx to Interest Expense		 90.37 68.39 38.77 52.32 53.52 49.97 36.21 98.81 91.66 73.24 78.67
NOPAT Less CapEx to Interest Expense		 60.38 50.81 40.23 42.12 46.74 39.98 39.77 51.38 59.22 71.32 34.42
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 46.90% 48.01% 58.23% 64.32% 59.56% 56.53% 47.06% 40.05% 41.24% 59.00% 74.53%

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

When does Regeneron Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Regeneron Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Regeneron Pharmaceuticals' net income changed over the last 9 years?

Regeneron Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $4.41 billion in 2024, rising from $636.06 million in 2015. The previous period was $3.95 billion in 2023.

What is Regeneron Pharmaceuticals's operating income?
Regeneron Pharmaceuticals's total operating income in 2024 was $3.99 billion, based on the following breakdown:
  • Total Gross Profit: $12.23 billion
  • Total Operating Expenses: $8.24 billion
How has Regeneron Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' total revenue changed from $4.10 billion in 2015 to $14.20 billion in 2024, a change of 246.1%.

How much debt does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals' total liabilities were at $8.41 billion at the end of 2024, a 18.3% increase from 2023, and a 330.1% increase since 2015.

How much cash does Regeneron Pharmaceuticals have?

In the past 9 years, Regeneron Pharmaceuticals' cash and equivalents has ranged from $535.20 million in 2016 to $3.11 billion in 2022, and is currently $2.49 billion as of their latest financial filing in 2024.

How has Regeneron Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' book value per share changed from 35.12 in 2015 to 267.12 in 2024, a change of 660.6%.


Related Companies

This page (NASDAQ:REGN) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Elon Musk’s next move from the Oval Office?
No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...
Weiss Ratings | Sponsored
China’s next move could destroy U.S. tech
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...
Investors Alley | Sponsored
This isn’t a trade war. It’s worse…
Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...
Stansberry Research | Sponsored
Top performing AI play of the decade…? (The answer will shock you)
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored